

Capital Change Notice

Section 1: Issuer information	
Name of issuer	Rua Bioscience Limited
NZX ticker code	RUA
Class of financial product	Ordinary shares
ISIN (If unknown, check on NZX website)	
Currency	NZD
Section 2: Capital change details	
Number issued /acquired/redeemed	8,140,000
Nominal value (if any)	N/A
Issue/acquisition/redemption price per security	N/A
Nature of the payment (for example, cash or other consideration)	Conversion of performance shares
Amount paid up (if not in full)	Paid in full
Percentage of total class of Financial Products issued/ acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence) ¹	4.90%
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	N/A
Reason for issue /acquisition/redemption and specific authority for issue /acquisition/redemption/ (the reason for change must be identified here)	Conversion of performance shares
Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/acquisition/redemption.	174,299,267
In the case of an acquisition of shares, whether those shares are to be held as treasury stock	N/A
Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	Listing rule 4.9.1(b)
Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)	N/A

 $^{\mathrm{1}}$ The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

Date of issue/acquisition/redemption ²	21/12/2022
Section 3: Authority for this announcement and contact person	
Name of person authorised to make this announcement	Hamish White
Contact person for this announcement	Hamish White
Contact phone number	
Contact email address	Hamish.white@ruabio.com
Date of release through MAP	21/12/2022

_

² Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).